To explore the correlation between COPZ2 and the prognosis in glioma, Kaplan–Meier analysis showed that patients with high expression of COPZ2 exhibited poor overall survival (OS) (Hazard Ratio (HR) = 2.82, p < 0.001), disease-specific survival (DSS) (HR = 3.01, p < 0.001), and progress free interval (PFI) (p = 2.27, p < 0.001) in TCGA database (Figure 3A). Here, COPZ2 is linked to central nervous system cancer.